Moderate to severe psoriasis treatment challenges through the era of biological drugs

Abstract

Biological therapy has revolutionized moderate to severe psoriasis treatment. However, despite being more effective than conventional systemic treatments, some patients do not respond or lose response to biotechnological treatments or develop drug-antibodies, interfering with its safety and efficacy. There are also clinical forms of the disease and patient profiles for which is pending further scientific evidence for more sustained therapeutic interventions. The continuous and more detailed knowledge of psoriasis pathophysiology has allowed identifying new therapeutic targets, which is expected to help overcome the challenges of individualized psoriasis treatment.

Female patients are less satisfied with biological treatment for psoriasis and experience more side‐effects than male patients: results from the prospective BioCAPTURE registry

“…For this purpose, the Treatment Satisfaction Questionnaire for Medication (TSQM) can provide insight into different domains of treatment satisfaction: effectiveness, convenience, global satisfaction and side‐effects . In general, treatment satisfaction with biologics is high, although we previously demonstrated that there still remains room for improvement in treatment satisfaction…”

MiR‐126 correlates with increased disease severity and promotes keratinocytes proliferation and inflammation while suppresses cells' apoptosis in psoriasis

“…Patient with psoriasis has a higher risk of developing multiple complications, including psoriatic arthritis, cardiovascular diseases, Crohn's disease, anxiety, and depression, all of them substantially contributing to increased morbidity and mortality . Although the application of topical therapy, physiotherapy, systemic therapy, and novel biological agents (such as tumor necrosis factor alpha [TNF‐α] inhibitor, interleukin [IL]‐12/23 inhibitor and IL‐17 inhibitor) have achieved a certain effect, the low response rate and high recurrence rate remain critical issues to clinicians . Therefore, it is of great importance to investigate the underlying mechanism of psoriasis and explore novel treatment target.…”

“…4,5 Although the application of topical therapy, physiotherapy, systemic therapy, and novel biological agents (such as tumor necrosis factor alpha [TNFα] inhibitor, interleukin [IL]-12/23 inhibitor and IL-17 inhibitor) have achieved a certain effect, the low response rate and high recurrence rate remain critical issues to clinicians. 1,[6][7][8] Therefore, it is of great importance to investigate the underlying mechanism of psoriasis and explore novel treatment target.…”

Kesesuaian Tata Laksana Psoriasis Dengan Panduan Praktik Klinis (Ppk) Di Rsupn Dr. Cipto Mangunkusumo

“…Genom ini merupakan penentu utama pada 50% psoriasis dengan kerentanan genetik. 4 Mekanisme peradangan kulit pada psoriasis cukup kompleks dan melibatkan berbagai sitokin, kemokin, dan faktor pertumbuhan yang mengakibatkan gangguan regulasi keratinosit, sel radang, dan pembuluh darah sehingga lesi tampak menebal dengan skuama tebal berlapis. 1,2 Sel T diketahui berperan penting dalam patogenesis lesi kulit psoriasis.…”